mitomycin C + capecitabine + bevacizumab

Mitomycin C + capecitabine + bevacizumab is a combination chemotherapy regimen used in the treatment of metastatic colorectal cancer (mCRC) and has been studied in other solid tumors. **Mitomycin C** is an antitumor antibiotic that inhibits DNA replication and transcription. **Capecitabine** is an oral prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor, within tumor cells, leading to inhibition of DNA synthesis. **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis required for tumor growth and progression. The combination aims for synergistic anticancer activity, as mitomycin C may upregulate thymidine phosphorylase, facilitating capecitabine activation, while bevacizumab disrupts the tumor blood supply. This regimen is administered intravenously (mitomycin C, bevacizumab) and orally (capecitabine). Clinical evidence supports its efficacy and tolerability as a first-line treatment in mCRC, with improved progression-free survival compared to capecitabine alone[4][7].

Other names

MAX regimen